Hepatotoxicity of antituberculosis drugs

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 547-566

  Verma, Sumita ^a   Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84995968336     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (98)

1. CDC. Trends in tuberculosis-United States 1998-2003. MMWR 2004; 53:209-14.
2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society. Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
3. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. August 8, 2003/52(31);735-9.
4. American Thoracic Society. Preventive therapy of tuberculosis infection. Am Rev Respir Dis 1974; 110:371-4.
5. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99(2):465-71.
6. Randolph H, Joseph S. Toxic hepatitis with jaundice occurring in a patient treated with isoniazid. JAMA 1953; 152(1):38-40.
7. Berte SJ, Dewlett HJ. Isoniazid and para-aminosalicylic acid toxicity in 513 cases: a study including high doses of INH and gastrointestinal intolerance to PAS. Dis Chest 1959; 36(2):146-51.
8. Berte SJ, Dimase JD, Christianson CS. Isoniazid, para-aminosalycylic acid, and streptomycin tolerance in 1,744 patients. An analysis of reactions to single drug and drug groups plus data on multiple reactions, type and time of reactions and desensitization. Am Rev Respir Dis 1964; 90:598-606.
9. American Thoracic Society. Chemoprophylaxis for the prevention of tuberculosis; a statement by an ad-hoc committee. Am Rev Respir Dis 1965; 96:558-60.
10. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71(6):1113-20.
11. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106(3):357-65.
12. Kopanoff DE, Snider DE, Jr., Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117(6):991-1001.
13. World Health Organization Collaborating Center for International Drug monitoring. Adverse drug reaction terminology (ART), 1979. (Accessed January 2006. at http://www.WHO-UMC.org)
14. Turktas H, Unsal M, Tulek N, Oruc O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuberc Lung Dis 1994; 75(1):58-60.
15. Parthasarathy R, Sarma GR, Janardhanam B, et al. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986; 67(2):99-108.
16. British Thoracic Association. A controlled trial of six month chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. Br J Dis Chest 1981; 75:141-53.
17. Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127(4):1304-11.
18. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51(2):132-6.
19. Ormerod LP. Analysis of frequency of drug reactions to antituberculosis drugs. Thorax 1994; 45:403-8.
20. Ormerod LP. Hepatotoxicity of antituberculosis drugs. Thorax 1996; 51:111-3.
21. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128(1):116-23.
22. Maddrey WC. Isoniazid-induced liver disease. Semin Liver Dis 1981; 1(2):129-33.
23. Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18(1):70-9.
24. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79(1):1-12.
25. Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther 1999; 289(2):695-702.
26. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 1980; 213(2):364-9.
27. Patrick RL, Black KC. Pathology and toxicity of repeated doses of hydrazine and 1,1-dimethylhydrazine in monkeys and rats. Ind Med Surg 1965; 34:430-5.
28. Sarich TC, Zhou T, Adams SP, Bain AI, Wall RA, Wright JM. A model of isoniazid-induced hepatotoxicity in rabbits. J Pharmacol Toxicol Methods 1995; 34(2):109-16.
29. Sarich TC, Adams SP, Wright JM. The role of L-thyroxine and hepatic reductase activity in isoniazidinduced hepatotoxicity in rabbits. Pharmacol Res 1998; 38(3):199-207.
30. Sinha BK. Activation of hydrazine derivatives to free radicals in the perfused rat liver: a pin trapping study. Biochim Biophys Acta 1987; 924:261-9.
31. Sinha BK, Motten AG. Oxidative metabolism of hydrazine. Evidence for nitrogen centered radicals formations. Biochem Biophys Res Commun 1982; 105(3):1044-51.
32. Yue J, Peng RX, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 2004; 25(5):699-704.
33. Sarich TC, Youssefi M, Zhou T, Adams SP, Walls RA, Wright JM. The role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Arch Toxicol 1996; 70:835-40.
34. Kleno TG, Kiehr B, Baunsgaard D, Sidelmann UG. Combination of “omics” data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers 2004; 9(2):116-38.
35. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006; 45(1):117-26.
36. McConnell JB, Powell-Jackson PR, Davis M, Williams R. Use of liver function tests as predictors of rifampicin metabolism in cirrhosis. Q J Med 1981; 50(197):77-82.
37. Mulder De Jong MT, Mulder RJ. Drugs used in the treatment of tuberculosis and leprosy. In: Dukes MUG, ed. Meyler’s Side Effects of Drugs, Vol. 1. Oxford: Excerpta Medica, 1977:676-89.
38. Cohn HD. Clinical studies with a new rifamycin derivative. J Clin Pharmacol J New Drugs 1969; 9(2):118-25.
39. Kenwright S, Levi AJ. Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein. Gut 1974; 15(3):220-6.
40. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996; 15(6):394-405.
41. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69(2):289-302.
42. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazidrifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118(3):461-6.
43. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986; 133(6):1072-5.
44. Dickinson DS, Bailey WC, Hirschowitz BI. The effect of acetylation status on isoniazid (INH) hepatitis. Am Rev Respir Dis 1977; 115:395.
45. Weber WW, Hein DW, Litwin A, Lower GM, Jr. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer. Fed Proc 1983; 42(14):3086-97.
46. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21(4):929-32.
47. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976; 84(2):181-92.
48. Snider DE, Jr., Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145(2 Pt 1):494-7.
49. Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159(5):560-4.
50. Farrell GC. Drug-Induced Liver Disease. Edinburgh, Scotland: Churchill Livingstone, 1994.
51. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6(2):295-8.
52. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975; 68(2):181-90.
53. Pessayre D, Bentata M, Degott C, et al. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 1977; 72(2):284-9.
54. Rothwell DL, Richmond DE. Hepatorenal failure with self-initiated intermittent rifampicin therapy. Br Med J 1974; 2(917):481-2.
55. Alford RH. Antimycobacterial agents. In: Mandell GL, Douglas RJ, Benett JE, eds. Principles and Practices of Infectious Diseases. 3rd ed. New York: Churchill Livingstone, 1990:350-61.
56. Mcdermott W, Ormond L, Muschenheim C, Deuschle K, McCune RM, Jr., Tompsett R. Pyrazinamideisoniazid in tuberculosis. Am Rev Tuberc 1954; 69(3):319-33.
57. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71(836):359-62.
58. Snider DE, Jr., Long MW, Cross FS, Farer LS. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial. Am Rev Respir Dis 1984; 129(4):573-9.
59. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22(3):211-4.
60. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs. isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123(1):102-6.
61. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976; 19(5 Pt 2):610-25.
62. Gurumurthy P, Krishnamurthy MS, Nazareth O, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984; 129(1):58-61.
63. Martinez-Roig A, Cami J, Llorens-Terol J, de la Torre R, Perich F. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics 1986; 77(6):912-5.
64. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35(4):883-9.
65. van den Brande P, van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152(5 Pt 1):1705-8.
66. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77(4):335-40.
67. Cross FS, Long MW, Banner AS, Snider DE, Jr. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. Am Rev Respir Dis 1980; 122(2):349-53.
68. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9(10):2026-30.
69. Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105(2):408-11.
70. Crippin JS. Acetaminophen hepatotoxicity: potentiation by isoniazid. Am J Gastroenterol 1993; 88(4):590-2.
71. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990; 111:799-800.
72. Muldrew KL, James LP, Coop L, et al. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 2002; 30:446-51.
73. Franks AL, Binkin NJ, Snider DE, Jr., Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989; 104(2):151-5.
74. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid deaths in one state. Am Rev Respir Dis 1989; 140:700-5.
75. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O’Brien RJ. Terry Beirn Community Programs for Clinical Research on AIDS, Adult AIDS Clinical Trials Group, Centers for Disease Control and Prevention. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 2004; 39(4):561-5.
76. Stephens EA, Taylor JA, Kaplan N, et al. Ethnic variations in the CYP2E1 gene:polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogemetics 1994; 4:185-92.
77. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37(4):924-30.
78. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166(7):916-9.
79. Buchanan N, Eyberg C, Davis MD. Isoniazid pharmacokinetics in kwashiorkor. S Afr Med J 1979; 56(8):299-300.
80. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50(3):436-9.
81. Acocella G, Bonollo L, Garimoldi M, Mainardi M, Tenconi LT, Nicolis F B. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut 1972; 13(1):47-53.
82. Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98(2):502-4.
83. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31(1):201-6.
84. McGlynn KA, Lustbader ED, Sharrar RG, Murphy EC, London WT. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis 1986; 134(4):666-8.
85. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871-6.
86. Fernandez-Villar A, Sopena B, Vazquez R, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003; 36(3):293-8.
87. Kumar A, Misra PK, Mehotra R, Govil YC, Rana GS. Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis? Am Rev Respir Dis 1991; 143(6):1350-2.
88. Adams PC, Arthur MJ, Boyer T D, et al. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 2004; 39(5):1204-12.
89. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97(2):439-45.
90. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10(8):1018-23.
91. Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, McIntyre N. Antituberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995; 8(8):1384-8.
92. Garg PK, Tandon RK. Antituberculous agents-induced liver injury. In: Deleve L, Kaplowitz N, Deleve L, Kaplowitz N, eds. Drug Induced Liver Disease. New York: Marcel Dekker Inc., 2002:505-17.
93. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63(9):1278-86.
94. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of post transplant tuberculosis. Transplantation 2002; 74(6):892-5.
95. Verma A, Dhawan A, Wade JJ, et al. Mycobacterium tuberculosis infection in pediatric liver transplant recipients. Pediatr Infect Dis J 2000; 19(7):625-30.
96. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients:impact and implications for management. Clin Infect Dis 1998; 27(5):1266-77.
97. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000; 69(1):64-9.
98. Saukkonen J, Cohn D, Jasmer R, et al. An official ATS Statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-52.